Anadis goes over
Friday, 06 June, 2008
Victorian biotech Anadis (ASX: ANX) has sold over $820,000 worth of new shares to its shareholders under its share purchase plan (SPP), raising over $70,000 more than was intended.
The company, which specialises in polyclonal antibodies, said it had originally only intended to raise $750,000 under the SPP, but because of overwhelming interest decided to sell more, raising $823,000.
The new funds will be used to help fund clinical trials, and ultimately commercialise new products, the company said.
Indigenous-led initiative to resurrect the South Island Giant Moa
New Zealand's Ngāi Tahu Research Centre has partnered with Colossal Biosciences and Sir Peter...
Abnormal brain protein targeted in Parkinson's study
Researchers have identified a new brain protein involved in the development of Parkinson's...
Epilepsy disease model treated in a laboratory dish
A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...
